Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca, Daiichi Sankyo, and Seagen
Description:
Breast Cancer is the most common cancer found in women, regardless
of race or ethnicity. According to the American Cancer Society,
there were an estimated 281,550 new cases of invasive breast cancer
in women in the United States during 2022. The incidence in women in
the United States is 1 in 8 (about 12 percent). About 46,600 women
were expected to die from breast cancer last year, though death
rates have been steadily decreasing over the past 20 years due to
new and ever improving treatment options. However, in the later
stages of disease, when distant metastases are present, cure becomes
less likely, and few patients are rendered free of disease. Therapy
in the advanced, metastatic setting then focuses on prolonging life
and managing disease-and treatment-related adverse events. There is
no single treatment strategy that will work for all patients with
metastatic breast cancer (MBC). Instead, treatment selection must be
individualized based upon patient- and tumor-specific factors, as
well as safety and efficacy profile of available agents, with an
emphasis on the combined goals of tumor control, prolonged survival,
and maintenance of patient quality of life. Fortunately for patients
with advanced breast cancer, several new agents, including small
molecule tyrosine kinase inhibitors (TKI), have recently been
approved, especially in HER2-positive disease and brain metastases.
They have shown the ability to improve safety and efficacy outcomes
in the approximately 40% of patients living with HER2-positive
advanced breast cancer. With these now available for the treatment
of metastatic breast cancer, it is critical to provide medical
directors, oncologists, practicing physicians and others on the
interprofessional management team with updated clinical data and
strategies on these new therapies the changing treatment paradigm,
with the ultimate goal of improving patient outcomes.
Upon completion of this
activity, participants will be able to:
-
Discuss the clinical and economic
burden of HER2-positive breast cancer in terms of relative
survival, mortality, drug utilization, adverse event management,
and hospitalizations
-
Evaluate efficacy and safety data
from practice-changing clinical trials for patients with
HER2-positive advanced breast cancer and the impact on evolving
treatment standards
-
Assess the role of HER2-directed
antibody-drug conjugates and tyrosine kinase inhibitors in the
treatment of patients with HER2-positive advanced breast cancer
and those with brain metastases
-
Examine recent updates for patients
who express low levels of HER2 who were traditionally unable to
receive HER2-directed therapies
-
Analyze strategies for anticipating,
recognizing, and managing adverse events of new and emerging
therapies, including antibody-drug conjugates and tyrosine
kinase inhibitors, in HER2-positive advanced breast cancer
-
Identify the role of managed care in
the evolving approach to diagnosing and treating HER2-positive
and HER2-low breast cancer
|
Faculty: |
Shanu Modi, MD
Member and Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Modi has served on an advisory board for AstraZeneca,
Daiichi Sankyo, Genentech, Gilead, Macrogenics, and
Seagen. She has served as a consultant for AstraZeneca,
Daiichi Sankyo, Genentech, Gilead, and Seagen. She has
received grant/research support from AstraZeneca,
Daiichi Sankyo, Genentech, and Seagen. She has served as
a speaker for AstraZeneca, Daiichi Sankyo, and Seagen.
Her presentation has been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
AstraZeneca, Daiichi Sankyo, and Seagen
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |